Mhn Prior Authorization Lookup
Latest Mhn prior authorization updates25
- Prior AuthAdministrative/Operational PolicyEff. 2026-04-01Prior Authorization (PA) requirements list for CHPIV Medi‑Cal FFS membersGoverns prior authorization and notification requirements for services, procedures, equipment, and outpatient pharmaceuticals for Community Health Plan of Imperial Valley (CHPIV) Medi‑Cal fee‑for‑service members in Imperial County; affects providers who must verify eligibility and submit PA requests as specified.All mhn updates
- Prior AuthAdministrative/Operational PolicyEff. 2026-04-01Prior Authorization Requirements — CalViva Health Medi‑Cal FFSGoverns prior authorization (PA) requirements, submission rules, timelines, and which services require PA for CalViva Health Medi‑Cal fee‑for‑service members in Fresno, Kings, and Madera counties.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2026-03-01Acalabrutinib (Calquence) coverageMedical necessity and prior authorization criteria for acalabrutinib (Calquence) for adult patients with mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and selected off-label B-cell malignancies; applies to providers and members covered under the payer's Commercial, HIM and Medicaid lines of business.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2026-02-01Proton and Neutron Beam TherapiesDefines medical necessity criteria and guidance for coverage of proton beam therapy (PBT) and neutron beam therapy (NBT) for members/enrollees of Centene-affiliated health plans; intended for clinicians and prior authorization reviewers.All mhn updates
- Prior AuthAdministrative/Operational PolicyEff. 2026-01-01Medicare outpatient prior authorization request form/processGovernance of outpatient prior authorization requests for Medicare members of Health Net California, including standard and expedited request workflows, required fields, and submission instructions; applies to providers requesting outpatient authorizations in California.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-12-01Brensocatib (Brinsupri) — Coverage Criteria for Non‑Cystic Fibrosis BronchiectasisDefines medical necessity criteria, authorization, and dosing for brensocatib (Brinsupri) for commercial, HIM, and Medicaid members and specifies requirements for prior authorization and continued therapy for patients age ≥12.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-12-01Clinical Policy: Aceclidine (Vizz)Clinical policy governing medical necessity and prior authorization criteria for aceclidine ophthalmic solution (Vizz) for treatment of presbyopia for Centene-affiliated health plans.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-12-01Clinical Policy: Gemcitabine Intravesical System (Inlexzo)This policy governs medical necessity and prior authorization criteria for Inlexzo (gemcitabine intravesical system) for treatment of BCG-unresponsive non-muscle invasive bladder cancer and related coverage rules for affected members and providers.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-12-01Clinical Policy: Paltusotine (Palsonify)Defines medical necessity criteria, dosing limits, prior authorization expectations, and approval durations for Palsonify (paltusotine) for adult members with acromegaly across Commercial, HIM, and Medicaid lines of business.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-12-01Delgocitinib (Anzupgo) topical for chronic hand eczemaDefines medical necessity, prior authorization, and continuation criteria for topical delgocitinib (Anzupgo) for chronic hand eczema in eligible members covered by the payer.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-12-01Dordaviprone (Modeyso) for diffuse midline gliomaDefines medical necessity criteria, dosing, and prior authorization requirements for Modeyso (dordaviprone) for members across Commercial, HIM, and Medicaid lines of business, focused on treatment of diffuse midline glioma with H3 K27M mutation. Applies to providers submitting requests for initial and continuation therapy.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-12-01Imlunestrant (Inluriyo) coverage for ER+/HER2- ESR1-mutated advanced/metastatic breast cancerDefines medical necessity and prior authorization requirements for Inluriyo (imlunestrant) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy; applies to commercial, HIM, and Medicaid lines of business.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-12-01Paltusotine (Palsonify) for acromegalyDefines medical necessity and prior authorization requirements for paltusotine (Palsonify) in adults with acromegaly for Centene-affiliated health plans (Commercial, HIM, Medicaid) and specifies approval durations and step therapy expectations.All mhn updates
- Prior AuthAdministrative/Operational PolicyEff. 2025-12-01Prior Authorization Requirements for CHPIV Medi‑Cal FFS ServicesThis document lists services, procedures, equipment, and outpatient pharmaceuticals that require prior authorization (PA) for Community Health Plan of Imperial Valley (CHPIV) Medi‑Cal fee‑for‑service members and explains submission, timelines, and related eligibility responsibilities.All mhn updates
- Prior AuthAdministrative/Operational PolicyEff. 2025-12-01Prior Authorization Requirements for CalViva Health Medi‑Cal FFS Members (Fresno, Kings, Madera Counties)This document lists services, procedures, equipment and outpatient pharmaceuticals that require prior authorization (PA) or notification for CalViva Health Medi‑Cal fee‑for‑service members in Fresno, Kings and Madera counties. It governs provider PA submission, timelines, and which categories require PA for adult and pediatric members.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-12-01Rilzabrutinib (Wayrilz)Defines medical necessity and prior authorization criteria for Wayrilz (rilzabrutinib) for adult patients with persistent or chronic immune thrombocytopenia (ITP) across specified lines of business.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-12-01Rilzabrutinib (Wayrilz) — Coverage Criteria for Immune ThrombocytopeniaDefines medical necessity and prior authorization criteria for rilzabrutinib (Wayrilz) for adults with persistent or chronic immune thrombocytopenia (ITP) across commercial, HIM, and Medicaid lines of business.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-12-01Zongertinib (Hernexeos) — Coverage Criteria for HER2‑mutant NSCLCMedical necessity and prior authorization criteria for zongertinib (Hernexeos) for adults with unresectable or metastatic nonsquamous NSCLC harboring HER2 (ERBB2) activating mutations; applies to Centene-affiliated health plans including Commercial, HIM, and Medicaid.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-10-01Clinical Policy: Linvoseltamab-gcpt (Lynozyfic)Defines medical necessity criteria, dosing limits, prior authorization and continuation requirements for Linvoseltamab-gcpt (Lynozyfic) for commercial, HIM and Medicaid lines of business. Includes excluded indications, dosing/administration, contraindications/boxed warnings, therapeutic alternatives, and coding implications.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-10-01Linvoseltamab-gcpt (Lynozyfic) coverageDefines medical necessity and prior authorization criteria for linvoseltamab-gcpt (Lynozyfic) for treatment of relapsed or refractory multiple myeloma in adults, and approval durations across lines of business.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-10-01Linvoseltamab-gcpt (Lynozyfic) for relapsed/refractory multiple myelomaDefines medical necessity, prior authorization, dosing limits, and coverage criteria for Linvoseltamab-gcpt (Lynozyfic) in adult patients with relapsed or refractory multiple myeloma across commercial, HIM, and Medicaid lines of business.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-09-25Clinical Policy: Alopecia Areata TreatmentsDefines medical necessity and prior authorization requirements for baricitinib (Olumiant), ritlecitinib (Litfulo), and deuruxolitinib (Leqselvi) for treating alopecia areata for applicable commercial and HIM lines of business.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-09-01Acoltremon (Tryptyr) for dry eye diseaseThis policy governs medical necessity and prior authorization criteria for Acoltremon (Tryptyr) when used to treat signs and symptoms of dry eye disease for affected health plan members across listed lines of business.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-09-01Clinical Policy: Avutometinib; Defactinib (Avmapki Fakzynja Co-Pack)Defines medical necessity criteria, initial and continued authorization requirements, dosing limits, contraindications, therapeutic alternatives, and prior authorization expectations for Avmapki Fakzynja Co-Pack across Commercial, HIM, and Medicaid lines of business.All mhn updates
- Prior AuthClinical/Medical PolicyEff. 2025-09-01Clinical Policy: Sunvozertinib (Zegfrovy)Defines medical necessity criteria and prior authorization requirements for sunvozertinib (Zegfrovy) for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations; applies to members covered by the payer's Commercial, HIM, and Medicaid lines of business.All mhn updates
1–25 of 856
1 / 35
Tool Description
Search Mhnprior authorization policies by drug name, procedure, or policy title. Results include any policy that mentions prior authorization requirements (drug coverage criteria, imaging guidelines, site-of-service rules) not just documents titled “prior authorization.” Every result links to a full policy page with clinical criteria, covered billing codes, documentation requirements, and effective dates.
Filter by payer, specialty, policy type, or effective year; or search directly for a drug (“Wegovy,” “Ozempic”), a procedure (“MRI,” “knee arthroplasty”), or a policy number.
Coverage spans 110+ payers. Jump straight to the busiest prior-auth publishers: UnitedHealthcare, Cigna, Aetna, Anthem, and Centene. You can also browse the full policy updates feed.
Pair a prior-auth search with the billing code lookup to confirm the CPT or J-code on the claim, the payer lookup for plan footprint, and payer profiles for contacts and coverage context.
FAQ
Type a drug name (“Wegovy,” “Ozempic”), a procedure (“MRI,” “knee”), or a policy title into the search bar. Filter results by payer, specialty, policy type, or effective year. Open any result for the full policy page with clinical criteria, covered billing codes, documentation requirements, and effective dates.
Prior Authorization by Payer
Go deeper
Explore OpenPayer Data
Prior auth requirements change all the time. Keep up with every payer policy update in the live policy feed, or browse payers with prior authorization policies.
Toolbox
More OpenPayer Tools
- Billing Code LookupSearch CPT, HCPCS, J-codes, DRG, and dental codes by number or procedure name.
- Healthcare Provider & Facility LookupFind hospitals and healthcare facilities by name, taxonomy, facility type, ownership, or state.
- Health Insurance Payer LookupSearch national health insurance payers and health plans by name and state presence.
- Provider Taxonomy Code LookupSearch NUCC taxonomy codes by code, specialty, grouping, or classification.
- CPT Modifier LookupSearch CPT modifiers by code or name — descriptions, when to use them, and payer policy context.
- Timely Filing LookupFind payer timely filing policies: claim deadlines, corrected claim windows, and appeal timeframes.
- Coverage Criteria LookupSearch payer coverage criteria and medical necessity requirements by drug, procedure, or payer.
- Payer Contact DirectoryClaims, prior authorization, provider services, and appeals contacts for health insurance payers.
Published by
Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.